Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New interview with Dr Coffey

<< Previous

Bullboard Posts

Next >>

Comment by Hand2Handon Nov 15, 2022 7:32pm

183 Views

Post# 35101685

RE:New interview with Dr Coffey

"Expect to start Registration in 6 to 9 months." They are definitely talking to the FDA at this moment.
"Investment potential in Oncolytics can be huge. Especially since they are 2 phase iii trials ready in two different indications."
Personally I can't understand why this company is still valued under 100 million.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments